SCHEMBL1015737

SCHEMBL1015737

CCCCCC(O)C(O)/C=C/C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
ACHE P22303 1/20 0.50
BACE1 P56817 1/20 0.50
GPR84 Q9NQS5 7/20 0.46
FFAR1 O14842 2/20 0.46
FFAR4 Q5NUL3 1/20 0.42
TRPA1 O75762 1/20 0.42
DDAH1 O94760 1/20 0.42
GAPDH P04406 1/20 0.42
MAPT P10636 1/20 0.42
SPHK1 Q9NYA1 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015738 1.00 FPR2 (0.56) FPR2NFKB1NFKB2RELAACHE
SCHEMBL25332329 0.86 FPR2 (0.62) FPR2NFKB1NFKB2RELAACHE
SCHEMBL17565690 0.85 FPR2 (0.53) FPR2NFKB1NFKB2RELAGPR84
SCHEMBL1958482 0.85 FPR2 (0.65) FPR2NFKB1NFKB2RELAACHE
SCHEMBL1958483 0.85 FPR2 (0.65) FPR2NFKB1NFKB2RELAACHE
SCHEMBL30140776 0.84 FPR2 (0.44) FPR2NFKB1NFKB2RELAACHE
SCHEMBL1506635 0.81 FPR2 (0.39) FPR2NFKB1NFKB2RELAACHE
SCHEMBL21552032 0.81 FPR2 (0.39) FPR2NFKB1NFKB2RELAACHE
SCHEMBL2494373 0.81 ACHE (0.68) FPR2NFKB1NFKB2RELAACHE
SCHEMBL2494371 0.81 ACHE (0.68) FPR2NFKB1NFKB2RELAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115515614-A Compositions comprising extracts of alpinia and other plants for improving joint health and treating arthritis 尤尼根公司 2022-12-23 CN disclosed
EP-4100034-A1 COMPOSITIONS COMPRISING EXTRACTS OF APLINIA AND OTHER PLANTS FOR IMPROVING JOINT HEALTH AND TREATING ARTHRITIS Unigen, Inc. (US) 2022-12-14 EP disclosed
US-20220000964-A1 Compositions and Methods for Regulating Homeostasis of Chondrocytes, Extracellular Matrix, Articular Cartilage, and Phenotype of Arthritis UNIGEN, INC. (US) 2022-01-06 US disclosed
WO-2021159042-A1 COMPOSITIONS COMPRISING EXTRACTS OF APLINIA AND OTHER PLANTS FOR IMPROVING JOINT HEALTH AND TREATING ARTHRITIS UNIGEN, INC. (US) 2021-08-12 WO disclosed
EP-1517880-B1 PRODUCTION OF CIS-PELLITORIN AND USE AS A FLAVOURING SYMRISE AG (DE) 2011-01-05 EP disclosed
US-7482479-B2 Production of cis-pellitorin and use as a flavouring SYMRISE GMBH & CO., KG (DE) 2009-01-27 US disclosed
US-20050234132-A1 Production of cis-pellitorin and use as a flavouring SYMRISE AG (DE) 2005-10-20 US disclosed
EP-1517880-A2 PRODUCTION OF CIS-PELLITORIN AND USE AS A FLAVOURING Symrise GmbH & Co. KG (DE) 2005-03-30 EP disclosed
WO-2004000787-A2 PRODUCTION OF CIS-PELLITORIN AND USE AS A FLAVOURING SYMRISE GMBH & CO. KG (DE) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234132-A1 Production of cis-pellitorin and use as a flavouring NISCH, CYP8B1, DLAT FPR2 1699/4885NFKB1 460/4885NFKB2 762/4885
US-20220000964-A1 Compositions and Methods for Regulating Homeostasis of Chondrocytes, Extracellular Matrix, Articular Cartilage, and Phenotype of Arthritis COL2A1, COL1A1, CKAP4 FPR2 4011/4885NFKB1 2329/4885NFKB2 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.